Johnson & Johnson (TSX:JNJ)

Market Cap	772.57B +51.0%
Revenue (ttm)	128.76B +6.0%
Net Income	36.64B +90.6%
EPS	15.08 +90.5%
Shares Out	n/a
PE Ratio	21.08
Forward PE	20.12
Dividend	0.67 (2.21%)
Ex-Dividend Date	Nov 25, 2025

Volume	5,459
Average Volume	5,915
Open	30.40
Previous Close	30.25
Day's Range	30.25 - 30.48
52-Week Range	18.90 - 30.48
Beta	n/a
RSI	79.54
Earnings Date	Jan 21, 2026

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo...

• Industry: Pharmaceutical Preparations
• Founded: 1886
• Employees: 138,100
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: JNJ

Financial Performance

In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.

Financial numbers in USD